2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precancerous Conditions
4
Colorectal Neoplasms
4
Breast Neoplasms
4
Adenomatous Polyposis Coli
4
Neoplasms
3
Colonic Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Tobacco Use Disorder
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Intraductal Neoplasms
1
Pain
1
Melanoma
1
Leukoplakia, Oral
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Hypertension
1
Desmoid Tumors
1
Coproporphyria
1
Colonic Polyps
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Aberrant Crypt Foci
1
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Monatide (IMS 3015)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Sulindac
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn